development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion

candesartan cilexetil (cc) is a newer class of angiotensin ii receptor antagonist used for the treatment of hypertension. the solubility of the cc is very poor and its oral bioavailability is only 15%. the controlled-release polar lipid microparticles of cc (formulations f1, f2, f3 and f4) were prepared using variable erodible lipophilic excipients like hydrogenated castor oil, stearic acid, cetostearyl alcohol and carnauba wax by fusion method. the particle sizes of polar lipid microparticles were less than 50 microns and they were irregular in shape. drug content ranged between 98.96 ± 2.1 and 101.9 ± 1.6% were present in all the formulations. the formulation f3 showed better drug release throughout the study period in a controlled release manner. moreover, the in vitro release showed that all the formulations were best fitted to higuchi model. accelerated stability studies indicated that there was no significant changes in the chemical and physical characteristics of the formulated drug product during initial and at the end of the study period . the ftir and dsc studies showed that there was no interaction between the drug and lipophilic excipients and no polymorphic transitions in all formulations. the x-ray diffraction peak of solid dispersion indicated that the crystalline nature of cc disappeared and no new peaks could be observed, suggesting the absence of interaction between drug and excipients.